Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

A cohort study of 49 933 women with surgically verified endometriosis: Increased incidence of breast cancer below the age of 40.

Saavalainen L, Lassus H, But A, Tiitinen A, Härkki P, Gissler M, Pukkala E, Heikinheimo O.

Acta Obstet Gynecol Scand. 2019 Sep;98(9):1113-1119. doi: 10.1111/aogs.13609. Epub 2019 Apr 8.

PMID:
30883685
2.

A Nationwide Cohort Study on the risk of non-gynecological cancers in women with surgically verified endometriosis.

Saavalainen L, Lassus H, But A, Tiitinen A, Härkki P, Gissler M, Heikinheimo O, Pukkala E.

Int J Cancer. 2018 Dec 1;143(11):2725-2731. doi: 10.1002/ijc.31721. Epub 2018 Sep 26.

PMID:
29981163
3.

Risk of Gynecologic Cancer According to the Type of Endometriosis.

Saavalainen L, Lassus H, But A, Tiitinen A, Härkki P, Gissler M, Pukkala E, Heikinheimo O.

Obstet Gynecol. 2018 Jun;131(6):1095-1102. doi: 10.1097/AOG.0000000000002624.

PMID:
29742675
4.

Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.

Niskakoski A, Pasanen A, Porkka N, Eldfors S, Lassus H, Renkonen-Sinisalo L, Kaur S, Mecklin JP, Bützow R, Peltomäki P.

Gynecol Oncol. 2018 Jul;150(1):92-98. doi: 10.1016/j.ygyno.2018.04.566. Epub 2018 Apr 30.

5.

Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance.

Niskakoski A, Pasanen A, Lassus H, Renkonen-Sinisalo L, Kaur S, Mecklin JP, Bützow R, Peltomäki P.

Mod Pathol. 2018 Aug;31(8):1291-1301. doi: 10.1038/s41379-018-0044-4. Epub 2018 Mar 27.

6.

L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.

Soovares P, Pasanen A, Bützow R, Lassus H.

Gynecol Oncol. 2017 Sep;146(3):615-622. doi: 10.1016/j.ygyno.2017.06.010. Epub 2017 Jun 16.

PMID:
28625395
7.

[Is endometriosis a premalignant condition to ovarian carcinoma?].

Lassus H, Pasanen A, Bützow R.

Duodecim. 2015;131(19):1777-84. Review. Finnish.

PMID:
26638662
8.

Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.

Niskakoski A, Kaur S, Staff S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R, Peltomäki P.

Epigenetics. 2014 Dec;9(12):1577-87. doi: 10.4161/15592294.2014.983374.

9.

Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.

Niskakoski A, Kaur S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R, Peltomäki P.

Int J Cancer. 2013 Dec 1;133(11):2596-608. doi: 10.1002/ijc.28287. Epub 2013 Jun 21.

10.

CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.

Paatero I, Lassus H, Junttila TT, Kaskinen M, Bützow R, Elenius K.

Gynecol Oncol. 2013 Apr;129(1):179-87. doi: 10.1016/j.ygyno.2012.12.044. Epub 2013 Jan 9.

PMID:
23313737
11.

A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer.

Li N, Kaur S, Greshock J, Lassus H, Zhong X, Wang Y, Leminen A, Shao Z, Hu X, Liang S, Katsaros D, Huang Q, Bützow R, Weber BL, Coukos G, Zhang L.

Cancer Res. 2012 Jan 1;72(1):154-64. doi: 10.1158/0008-5472.CAN-11-2484. Epub 2011 Nov 4.

12.

Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.

Linder N, Bützow R, Lassus H, Lundin M, Lundin J.

Gynecol Oncol. 2012 Feb;124(2):311-8. doi: 10.1016/j.ygyno.2011.10.026. Epub 2011 Oct 29.

PMID:
22044687
13.

Prognostic role of CIP2A expression in serous ovarian cancer.

Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A.

Br J Cancer. 2011 Sep 27;105(7):989-95. doi: 10.1038/bjc.2011.346. Epub 2011 Sep 6.

14.

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.

Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL, Degenhardt Y.

Genes Chromosomes Cancer. 2011 Aug;50(8):606-18. doi: 10.1002/gcc.20883. Epub 2011 May 11.

15.

Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells.

Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, Lassus H, Wang L, Katsaros D, Montone K, Zhao X, Zhang Y, Bützow R, Coukos G, Zhang L.

Cancer Res. 2010 Nov 15;70(22):9463-72. doi: 10.1158/0008-5472.CAN-10-2388. Epub 2010 Nov 2.

16.

Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.

Lassus H, Staff S, Leminen A, Isola J, Butzow R.

Gynecol Oncol. 2011 Jan;120(1):11-7. doi: 10.1016/j.ygyno.2010.09.003. Erratum in: Gynecol Oncol. 2012 Apr;125(1):282-3.

PMID:
20937525
17.

Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Bayani J, Marrano P, Graham C, Zheng Y, Li L, Katsaros D, Lassus H, Butzow R, Squire JA, Diamandis EP.

Mol Oncol. 2011 Feb;5(1):48-60. doi: 10.1016/j.molonc.2010.08.002. Epub 2010 Aug 11.

18.

Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Bützow R, Coukos G, Zhang L.

PLoS One. 2010 Apr 21;5(4):e10277. doi: 10.1371/journal.pone.0010277.

19.

Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas.

Karlberg S, Lipsanen-Nyman M, Lassus H, Kallijärvi J, Lehesjoki AE, Butzow R.

Mod Pathol. 2009 Apr;22(4):570-8. doi: 10.1038/modpathol.2009.13. Epub 2009 Mar 27.

20.

MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.

Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Bützow R, Croce CM, Coukos G, Zhang L.

Cancer Res. 2008 Dec 15;68(24):10307-14. doi: 10.1158/0008-5472.CAN-08-1954.

21.

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.

Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9. doi: 10.1073/pnas.0801615105. Epub 2008 May 5.

22.

Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.

Vartiainen J, Lassus H, Lehtovirta P, Finne P, Alfthan H, Butzow R, Stenman UH.

Int J Cancer. 2008 May 1;122(9):2125-9.

23.

The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.

Lassus H, Butzow R.

Br J Cancer. 2007 May 21;96(10):1621-2; author reply 1623-4. Epub 2007 Apr 17. No abstract available.

24.

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.

Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R.

J Mol Med (Berl). 2006 Aug;84(8):671-81. Epub 2006 Apr 11.

PMID:
16607561
25.

Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma.

Erkinheimo TL, Sivula A, Lassus H, Heinonen M, Furneaux H, Haglund C, Butzow R, Ristimäki A.

Gynecol Oncol. 2005 Oct;99(1):14-9.

PMID:
16126263
26.

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.

Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN, Butzow R.

Br J Cancer. 2004 Dec 13;91(12):2048-55.

27.

Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.

Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, Ylikorkala O, Haglund C, Butzow R, Ristimäki A.

Clin Cancer Res. 2004 Jan 15;10(2):538-45.

28.

ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.

Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, Butzow R.

Gynecol Oncol. 2004 Jan;92(1):31-9.

PMID:
14751135
29.

Distinct subtypes of serous ovarian carcinoma identified by p53 determination.

Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R.

Gynecol Oncol. 2003 Dec;91(3):504-12.

PMID:
14675668
30.

Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.

Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R, Ristimäki A.

Cancer Res. 2003 Nov 15;63(22):7591-4.

31.

Glycodelin in ovarian serous carcinoma: association with differentiation and survival.

Mandelin E, Lassus H, Seppälä M, Leminen A, Gustafsson JA, Cheng G, Bützow R, Koistinen R.

Cancer Res. 2003 Oct 1;63(19):6258-64.

32.

Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients.

Moilanen J, Lassus H, Leminen A, Vaheri A, Bützow R, Carpén O.

Gynecol Oncol. 2003 Aug;90(2):273-81.

PMID:
12893187
33.
34.

Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4.

Lassus H, Laitinen MP, Anttonen M, Heikinheimo M, Aaltonen LA, Ritvos O, Butzow R.

Lab Invest. 2001 Apr;81(4):517-26.

Supplemental Content

Loading ...
Support Center